Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 247, Issue -, Pages 115047
Publisher
Elsevier BV
Online
2022-12-26
DOI
10.1016/j.ejmech.2022.115047
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial
- (2022) Jiang Wang et al. Cell Metabolism
- A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α
- (2020) Xuelei Wang et al. EBioMedicine
- In Search for Genes Related to Atherosclerosis and Dyslipidemia Using Animal Models
- (2020) Anastasia V. Poznyak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Statin-Associated Autoimmune Myopathy: Current Perspectives
- (2020) Eleni Tiniakou Therapeutics and Clinical Risk Management
- From Methylene Bridged Diindole to Carbonyl Linked Benzimidazoleindole: Development of Potent and Metabolically Stable PCSK9 Modulators
- (2020) Haibo Xie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 2,3′-diindolylmethanes as a novel class of PCSK9 modulators
- (2019) Gabrielle N. Winston-McPherson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The Global Burden of Cardiovascular Diseases and Risk Factors
- (2019) George A. Mensah et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein MetabolismHighlights
- (2018) Dick C. Chan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Small Molecule Inhibitors of the PCSK9·LDLR Interaction
- (2018) Jaru Taechalertpaisarn et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Inhibiting Translation One Protein at a Time
- (2017) Matthew D. Disney TRENDS IN BIOCHEMICAL SCIENCES
- PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
- (2017) Andrea Baragetti et al. European Journal of Preventive Cardiology
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
- (2016) Anne Langsted et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator
- (2015) Huajun Jiang et al. ATHEROSCLEROSIS
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search